OSE Immunotherapeutics SA: OSE Immunotherapeutics Reports Full Year 2022 Financial Results and Provides Business Strategy Update : vimarsana.com

Financial highlights 2022 total turnover of €18 million driven by strategic partnerships with pharmaceutical companies. €25.6 million available cash as of December 31st 2022, including

Related Keywords

University Hospital , Texas , United States , Australia , Malaysia , Pakistan , Houston , Spain , China , New Zealand , Colombia , Mexico , El Salvador , Italy , Ukraine , Macao , Macau General , Macau , Boston , Massachusetts , Japan , Israel , Taiwan , Russia , France , Paris , France General , American , Salvador , French , Ukrainian , Anne Laure Autret Cornet , Florence Portejoie , Elise Chiffoleau , Nicolas Poirier , Miriam Merad Mount , Charles Serhan Harvard , Sophie Brouard , Alexandre Lebeaut , Fridman Universit , Thomas Guillot , Novartis , Food Drug Administration , Linkedin , Health Agencies In Europe , Nantes University At Hospital , Chili , Veloxis Pharmaceuticals Inc , Society For Immunotherapy Of Cancer , American Society Of Clinical Oncology , Boehringer Ingelheim , Nantes University Hospital , European Investment Bank , Audit Committee , American Society Of Hematology , Club Des Trente , Company Board Of Directors The , European Society For Medical Oncology , American Association For Cancer Research , Jennifer Wargo Md Anderson Cancer Center , Twitter , Drug Administration , Schering Plough Research Institute , European Investment , Clinical Phase , Chief Executive Officer , Region Pays De La Loire , Laure Autret Cornet , Chief Financial Officer , European Medicines Agencies , Immune Checkpoint Inhibitors , Health Agencies , Special Situation , Special Situation Authorization , Real Decreto , American Society , Clinical Oncology , European Society , Medical Oncology , Patient Reported Outcomes , Net Treatment Benefit , Maximum Tolerated Dose , T Cell Acute Lymphoblastic Leukemia , Acute Lymphoblastic Leukemia Development Via , Dual Mode , Veloxis Pharmaceuticals , Fast Track Designation , Protein Antibody Engineering Summit , Immuno Oncology Summit Europe , Tumor Myeloid Directed Therapies Summit , Translational Immunology , Nantes University , American Association , Cancer Research , Tumor Infiltrating Lymphocytes , Independent Member , Bluebird Bio , Schering Plough Research , Chief Scientific Officer , Bernard Malissen , Miriam Merad , Mount Sinai , Charles Serhan , Jennifer Wargo , Cancer Center , Vester Finance , Des March , Prospectus Regulation , French State , Non Small Cell Lung Cancer , Universal Registration Document , Immunotherapeutics , Eports , Ull , Ear , 022 , Inancial , Esults , Rovides , Usiness , Trategy , Pdate ,